Do analysts rate MOR or RDY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Do analysts prefer SMMT or MOR?

Summit Therapeutics currently has a consensus price target of $27.23, suggesting a potential upside of 94.33%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Summit Therapeutics is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 2 Sell rating(s) 6 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.47 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend ARWR or MOR?

Arrowhead Pharmaceuticals currently has a consensus price target of $87.80, indicating a potential upside of 17.82%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arrowhead Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.75 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate RGC or MOR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, RGC or MOR?

Regencell Bioscience has higher earnings, but lower revenue than MorphoSys. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A

Do analysts prefer NUVL or MOR?

Nuvalent presently has a consensus price target of $131.15, suggesting a potential upside of 6.41%. Given Nuvalent's stronger consensus rating and higher possible upside, equities analysts plainly believe Nuvalent is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 1 Sell rating(s) 14 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.20 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, NUVL or MOR?

MorphoSys has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvalent N/A N/A -$425.38M -$6.06 N/A MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A

Is NUVL or MOR more profitable?

Nuvalent has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Nuvalent's return on equity of -40.11% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets Nuvalent N/A -40.11% -35.43% MorphoSys -226.79% -694.31% -22.55%

MorphoSys (MOR) Competitors

$18.96 0.00 (0.00%)

As of 06/12/2026

Compare

MOR vs. RDY, SMMT, ARWR, RGC, and NUVL

Should you buy MorphoSys stock or one of its competitors? MarketBeat compares MorphoSys with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MorphoSys include Dr. Reddy's Laboratories (RDY), Summit Therapeutics (SMMT), Arrowhead Pharmaceuticals (ARWR), Regencell Bioscience (RGC), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.

How does MorphoSys compare to Dr. Reddy's Laboratories?

MorphoSys (NASDAQ:MOR) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to MorphoSys' net margin of -226.79%. Dr. Reddy's Laboratories' return on equity of 12.34% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

Dr. Reddy's Laboratories has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Dr. Reddy's Laboratories	$3.58B	3.10	$456M	$0.58	22.94

In the previous week, Dr. Reddy's Laboratories had 1 more articles in the media than MorphoSys. MarketBeat recorded 1 mentions for Dr. Reddy's Laboratories and 0 mentions for MorphoSys. MorphoSys' average media sentiment score of 0.00 equaled Dr. Reddy's Laboratories'average media sentiment score.

Company	Overall Sentiment
MorphoSys	Neutral
Dr. Reddy's Laboratories	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

Summary

Dr. Reddy's Laboratories beats MorphoSys on 10 of the 13 factors compared between the two stocks.

How does MorphoSys compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

Summit Therapeutics currently has a consensus price target of $27.23, suggesting a potential upside of 94.33%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Summit Therapeutics is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summit Therapeutics has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Summit Therapeutics' return on equity of -291.24% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
MorphoSys	-226.79%	-694.31%	-22.55%

MorphoSys has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Summit Therapeutics has a beta of -1.32, suggesting that its stock price is 232% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

In the previous week, Summit Therapeutics had 13 more articles in the media than MorphoSys. MarketBeat recorded 13 mentions for Summit Therapeutics and 0 mentions for MorphoSys. Summit Therapeutics' average media sentiment score of 0.84 beat MorphoSys' score of 0.00 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Summit Therapeutics	Positive
MorphoSys	Neutral

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Comparatively, 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Summit Therapeutics beats MorphoSys on 10 of the 16 factors compared between the two stocks.

How does MorphoSys compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

Arrowhead Pharmaceuticals currently has a consensus price target of $87.80, indicating a potential upside of 17.82%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Arrowhead Pharmaceuticals has higher revenue and earnings than MorphoSys. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	12.66	-$1.63M	-$2.15	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Arrowhead Pharmaceuticals has a net margin of -48.38% compared to MorphoSys' net margin of -226.79%. Arrowhead Pharmaceuticals' return on equity of -55.09% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
MorphoSys	-226.79%	-694.31%	-22.55%

In the previous week, Arrowhead Pharmaceuticals had 10 more articles in the media than MorphoSys. MarketBeat recorded 10 mentions for Arrowhead Pharmaceuticals and 0 mentions for MorphoSys. Arrowhead Pharmaceuticals' average media sentiment score of 1.62 beat MorphoSys' score of 0.00 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Arrowhead Pharmaceuticals	Very Positive
MorphoSys	Neutral

Arrowhead Pharmaceuticals has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Summary

Arrowhead Pharmaceuticals beats MorphoSys on 16 of the 17 factors compared between the two stocks.

How does MorphoSys compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and MorphoSys (NASDAQ:MOR) are both mid-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Regencell Bioscience has higher earnings, but lower revenue than MorphoSys.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Regencell Bioscience has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

Regencell Bioscience has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Regencell Bioscience's return on equity of 0.00% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
MorphoSys	-226.79%	-694.31%	-22.55%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Regencell Bioscience had 21 more articles in the media than MorphoSys. MarketBeat recorded 21 mentions for Regencell Bioscience and 0 mentions for MorphoSys. Regencell Bioscience's average media sentiment score of 0.14 beat MorphoSys' score of 0.00 indicating that Regencell Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Regencell Bioscience	Neutral
MorphoSys	Neutral

Summary

Regencell Bioscience beats MorphoSys on 8 of the 11 factors compared between the two stocks.

How does MorphoSys compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and MorphoSys (NASDAQ:MOR) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

Nuvalent has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Nuvalent has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Nuvalent's return on equity of -40.11% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
MorphoSys	-226.79%	-694.31%	-22.55%

In the previous week, Nuvalent had 60 more articles in the media than MorphoSys. MarketBeat recorded 60 mentions for Nuvalent and 0 mentions for MorphoSys. Nuvalent's average media sentiment score of 0.18 beat MorphoSys' score of 0.00 indicating that Nuvalent is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvalent	Neutral
MorphoSys	Neutral

MorphoSys has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Nuvalent presently has a consensus price target of $131.15, suggesting a potential upside of 6.41%. Given Nuvalent's stronger consensus rating and higher possible upside, equities analysts plainly believe Nuvalent is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	14 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Nuvalent beats MorphoSys on 9 of the 15 factors compared between the two stocks.

Get MorphoSys News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MOR vs. The Competition

Export

Metric	MorphoSys	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.86B	$759.83M	$6.74B	$12.07B
Dividend Yield	N/A	4.84%	2.67%	5.67%
P/E Ratio	-5.45	1.45	24.21	24.42
Price / Sales	11.99	120.48	512.04	109.94
Price / Cash	N/A	20.06	27.48	37.92
Price / Book	54.17	7.85	10.66	6.83
Net Income	-$205.35M	-$4.88M	$3.57B	$337.67M
7 Day Performance	N/A	0.64%	0.58%	1.17%
1 Month Performance	N/A	-0.16%	1.54%	3.16%
1 Year Performance	N/A	47.51%	25.40%	30.58%

MorphoSys Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
RDY Dr. Reddy's Laboratories	1.3256 of 5 stars	$13.32 -0.4%	N/A	-15.8%	$11.16B	$3.58B	22.96	27,527
SMMT Summit Therapeutics	3.7812 of 5 stars	$13.05 -8.7%	$26.05 +99.6%	-29.2%	$11.09B	N/A	N/A	110	News Coverage Insider Trade
ARWR Arrowhead Pharmaceuticals	2.78 of 5 stars	$70.73 -3.5%	$87.80 +24.1%	+373.4%	$10.33B	$829.45M	N/A	400	News Coverage Positive News
RGC Regencell Bioscience	0.2966 of 5 stars	$20.45 +0.7%	N/A	N/A	$10.04B	N/A	N/A	10	Trending News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MOR) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MorphoSys (MOR) Competitors

MOR vs. RDY, SMMT, ARWR, RGC, and NUVL

How does MorphoSys compare to Dr. Reddy's Laboratories?

Summary

How does MorphoSys compare to Summit Therapeutics?

Summary

How does MorphoSys compare to Arrowhead Pharmaceuticals?

Summary

How does MorphoSys compare to Regencell Bioscience?

Summary

How does MorphoSys compare to Nuvalent?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOR vs. The Competition

MorphoSys Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MorphoSys (MOR) Competitors

MOR vs. RDY, SMMT, ARWR, RGC, and NUVL

How does MorphoSys compare to Dr. Reddy's Laboratories?

Is MOR or RDY more profitable?

Which has better valuation and earnings, MOR or RDY?

Does the media refer more to MOR or RDY?

Do analysts rate MOR or RDY?

Do insiders & institutionals believe in MOR or RDY?

Which has more volatility and risk, MOR or RDY?

Summary

How does MorphoSys compare to Summit Therapeutics?

Do analysts prefer SMMT or MOR?

Is SMMT or MOR more profitable?

Which has better earnings and valuation, SMMT or MOR?

Which has more risk & volatility, SMMT or MOR?

Does the media prefer SMMT or MOR?

Do institutionals & insiders hold more shares of SMMT or MOR?

Summary

How does MorphoSys compare to Arrowhead Pharmaceuticals?

Do analysts recommend ARWR or MOR?

Do insiders and institutionals believe in ARWR or MOR?

Which has higher valuation and earnings, ARWR or MOR?

Is ARWR or MOR more profitable?

Does the media prefer ARWR or MOR?

Which has more risk & volatility, ARWR or MOR?

Summary

How does MorphoSys compare to Regencell Bioscience?

Which has preferable valuation and earnings, RGC or MOR?

Do institutionals and insiders believe in RGC or MOR?

Which has more volatility & risk, RGC or MOR?

Is RGC or MOR more profitable?

Do analysts rate RGC or MOR?

Does the media refer more to RGC or MOR?

Summary

How does MorphoSys compare to Nuvalent?

Which has more volatility & risk, NUVL or MOR?

Is NUVL or MOR more profitable?

Does the media refer more to NUVL or MOR?

Which has stronger earnings & valuation, NUVL or MOR?

Do insiders & institutionals have more ownership in NUVL or MOR?

Do analysts prefer NUVL or MOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOR vs. The Competition

MorphoSys Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools